Loading...
XSHE002653
Market cap5.11bUSD
Dec 26, Last price  
33.22CNY
1D
-1.54%
1Q
1.56%
Jan 2017
135.91%
IPO
528.43%
Name

Haisco Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002653 chart
P/E
126.07
P/S
11.09
EPS
0.26
Div Yield, %
0.00%
Shrs. gr., 5y
0.72%
Rev. gr., 5y
-0.42%
Revenues
3.36b
+11.27%
358,762,468484,571,191581,585,122604,429,653802,069,348992,337,3021,210,595,3831,212,453,3431,435,606,5861,856,160,9253,426,664,2593,937,340,4623,329,599,5742,773,314,8843,015,294,3393,355,070,108
Net income
295m
-24.65%
195,086,739283,719,337305,752,954312,296,110443,060,913519,218,912450,541,060372,157,949452,723,897237,553,210333,228,517493,891,812636,621,367517,582,477391,644,290295,111,611
CFO
450m
+375.51%
94,445,426368,213,627367,380,976260,794,014464,751,585568,414,763502,568,128443,027,933426,111,876391,810,909472,607,295764,259,511206,207,63635,801,45994,546,036449,578,350
Dividend
Sep 18, 20240.145 CNY/sh

Profile

Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers small-volume injections, freeze-dried powder injections, powder injections, large-volume injections, active pharmaceutical ingredient, etc. for various therapeutic fields, including anti-infective, digestive system, blood system, nervous system, parenteral nutrition, antibiotics, first aid, anesthetics, and tumor; and tablets, capsules, granules, and ointments in the fields of cardiovascular, anti-infection, digestive system, CNS system, diabetes, and hepatic diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.
URL
http://www.haisco.com/
IPO date
Jan 17, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,355,070
11.27%
3,015,294
8.73%
2,773,315
-16.71%
Cost of revenue
2,269,245
2,579,421
2,439,953
Unusual Expense (Income)
NOPBT
1,085,825
435,874
333,361
NOPBT Margin
32.36%
14.46%
12.02%
Operating Taxes
6,960
Tax Rate
0.64%
NOPAT
1,078,866
435,874
333,361
Net income
295,112
-24.65%
391,644
-24.33%
517,582
-18.70%
Dividends
(199,187)
(399,706)
Dividend yield
0.83%
1.84%
Proceeds from repurchase of equity
(8,162)
(1)
(1)
BB yield
0.03%
0.00%
0.00%
Debt
Debt current
954,431
786,734
785,958
Long-term debt
876,376
1,320,494
474,220
Deferred revenue
108,473
98,520
102,541
Other long-term liabilities
108,852
8,706
2
Net debt
18,658
706,503
120,539
Cash flow
Cash from operating activities
449,578
94,546
35,801
CAPEX
(391,009)
Cash from investing activities
(383,190)
281,970
Cash from financing activities
328,066
624,230
FCF
947,539
163,504
406,948
Balance
Cash
1,328,767
775,390
575,112
Long term investments
483,381
625,335
564,527
Excess cash
1,644,395
1,249,960
1,000,974
Stockholders' equity
3,341,126
3,071,733
2,883,408
Invested Capital
4,454,956
4,045,560
3,241,348
ROIC
25.38%
11.96%
10.18%
ROCE
17.79%
8.23%
7.86%
EV
Common stock shares outstanding
1,114,118
1,075,607
1,076,686
Price
23.15
4.04%
22.25
10.34%
20.17
18.08%
Market cap
25,791,831
7.77%
23,932,266
10.23%
21,711,782
18.86%
EV
25,801,134
24,736,450
21,910,594
EBITDA
1,305,409
619,997
486,549
EV/EBITDA
19.76
39.90
45.03
Interest
42,279
50,912
27,156
Interest/NOPBT
3.89%
11.68%
8.15%